Combined trial is ongoing also in PCa, a phase II clinical trial (NCT02601014) is currently enrolling mCRPC patients with detectable androgen receptor-variant-7 (AR-V7), (tumor cells expressing AR-V7 has been shown to be resistant to hormone therapy and some chemotherapies). This evidence concerns the gene AR and neoplasm.